Cargando…
AAV9-TAZ Gene Replacement Ameliorates Cardiac TMT Proteomic Profiles in a Mouse Model of Barth Syndrome
Barth syndrome (BTHS) is a rare mitochondrial disease that causes severe cardiomyopathy and has no disease-modifying therapy. It is caused by recessive mutations in the gene tafazzin (TAZ), which encodes tafazzin—an acyltransferase that remodels the inner mitochondrial membrane lipid cardiolipin. To...
Autores principales: | Suzuki-Hatano, Silveli, Saha, Madhurima, Soustek, Meghan S., Kang, Peter B., Byrne, Barry J., Cade, W. Todd, Pacak, Christina A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369239/ https://www.ncbi.nlm.nih.gov/pubmed/30788385 http://dx.doi.org/10.1016/j.omtm.2019.01.007 |
Ejemplares similares
-
Increased mtDNA Abundance and Improved Function in Human Barth Syndrome Patient Fibroblasts Following AAV-TAZ Gene Delivery
por: Suzuki-Hatano, Silveli, et al.
Publicado: (2019) -
One episode of low intensity aerobic exercise prior to systemic AAV9 administration augments transgene delivery to the heart and skeletal muscle
por: Pacak, Christina A., et al.
Publicado: (2023) -
Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe mice
por: Falk, Darin J, et al.
Publicado: (2015) -
Elevated liver glycogenolysis mediates higher blood glucose during acute exercise in Barth syndrome
por: Schweitzer, George G., et al.
Publicado: (2023) -
Impaired cardiac and skeletal muscle bioenergetics in children, adolescents, and young adults with Barth syndrome
por: Bashir, Adil, et al.
Publicado: (2017)